Details of the Drug

General Information of Drug (ID: DMTY169)

Drug Name

Norethindrone

Synonyms

Activella; Anhydrohydroxynorprogesterone; Anovulatorio; Anovule; Brevicon; Brevinor; Camila; Ciclovulan; Conceplan;Conludaf; Conludag; Demulen; Errin; Estrinor; Ethinylnortestosterone; Ethynylmortestosterone; Ethynylnortestosterone; Gencept; Genora; Gestest; Jenest; Loestrin; Menzol; Microneth; Micronett; Micronor; Micronovum; Milli; Minovlar; Nelova; Nodiol; Noraethisteronum; Noralutin; Norcept; Norcolut; Norcolute; Noresthisterone; Norethadrone; Norethin; Norethindirone; Norethisteron; Norethisterone; Norethisteronum; Norethyndron; Norethynodron; Norethynodrone; Noretisterona; Noretisterone; Norfor; Norgestin; Noriday; Norluten; Norlutin; Norluton; Normapause; Norpregneninlone; Norpregneninolone; Norpregneninotone; Orlest; Proluteasi; Synphase; Triella; Utovlan; Utovlar; Component of Noriday; Norethindrone Norethisterone; Norethindrone [USAN]; Norethisterone [Progestins]; Noretisterone [DCIT]; Primolut N; Brevinor 21; Brevinor 28; Noriday 28; Ortho 1 35; Ortho 7 7 7; Ovysmen 1 35; SC 4640; Synphasic 28; Trinovum 21; Brevinor-1 21; Brevinor-1 28; Camila (TN); Jenest-28; Micronor (TN); Mini-Pe; Mini-pill; Nor-QD; Nora-BE; Norcept-E; Norethin 1/35 E; Norethin 1/50 M; Norethindrone (USP); Norethisterone (JP15); Norethisteronum [INN-Latin]; Noretisterona [INN-Spanish]; Ortho-Novum 1 35; Ortho-Novum 1 50; Ortho-Novum 7 7 7; Ovysmen 0.5 35; Primolut-N; Tri-Norinyl; Ethinyl-19-nortestosterone; Nor-Q.D; Primolut-N (TN); Nor-Q.D.; 17-Ethinyl-19-nortestosterone; 17-Ethynyl-17-hydroxyestr-4-en-3-one; 17-alpha-Ethynyl-19-nortestosterone; 17-alpha-Ethynyl-4-estren-17-ol-3-one; 17-ethynyl-17beta-hydroxyestr-4-en-3-one; 17.alpha.-Ethinyl-19-nortestosterone; 17.alpha.-Ethynyl-19-nortestosterone; 17.alpha.-Ethynyl-4-estren-17-ol-3-one; 17alpha-Ethinyl-19-nortestosterone; 17alpha-Ethynyl-19-nortestosterone; 17alpha-Ethynyl-4-estren-17-ol-3-one; 19-Nor-17-alpha-ethynyltestosterone; 19-Nor-17-ethinyltestosterone; 19-Nor-17.alpha.-ethynyltestosterone; 19-Nor-17alpa-ethynyltestosterone; 19-Nor-17alpha-ethynyltestosterone; 19-Nor-ethindrone; 19-Nor-ethinyl-4,5-testosterone; 19-Norethindrone; 19-Norethinyltestosterone; 19-Norethisterone; 4-Estren-17alpha-ethynyl-17beta-ol-3-one

Indication

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[1]
Advanced cancer	2A00-2F9Z	Approved	[1]
Hot flushes	GA30	Approved	[1]
Menorrhagia	GA20.50	Approved	[1]
Obsolete atrophic vulva	N.A.	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Approved	[2]
Endometriosis	GA10	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Contraceptive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

298.4

Logarithm of the Partition Coefficient (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: 64% of drug becomes completely available to its intended biological destination(s) [4]
Elimination: 2% of drug is excreted from urine in the unchanged form [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.01675 micromolar/kg/day [5]
Water Solubility: The ability of drug to dissolve in water is measured as 0.01 mg/mL [3]

Chemical Identifiers

Formula: C20H26O2
IUPAC Name: (8R,9S,10R,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
Canonical SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34
InChI: InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1
InChIKey: VIKNJXKGJWUCNN-XGXHKTLJSA-N

Cross-matching ID

PubChem CID: 6230
ChEBI ID: CHEBI:7627
CAS Number: 68-22-4
DrugBank ID: DB00717
TTD ID: D0GL7U
ACDINA ID: D00478

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Progesterone receptor (PGR)	TTUV8G9	PRGR_HUMAN	Agonist	[6]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Gene/Protein Processing	[7]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Gene/Protein Processing	[7]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[8]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Gene/Protein Processing	[9]
Fatty acid synthase (FASN)	OTFII9KG	FAS_HUMAN	Gene/Protein Processing	[10]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Post-Translational Modifications	[11]
Microtubule-associated protein tau (MAPT)	OTMTP2Z7	TAU_HUMAN	Gene/Protein Processing	[12]
Myb-related protein A (MYBL1)	OTBJMC2P	MYBA_HUMAN	Gene/Protein Processing	[13]
Osteocalcin (BGLAP)	OTK1YLWQ	OSTCN_HUMAN	Protein Interaction/Cellular Processes	[14]
Protein GREB1 (GREB1)	OTU6ZA26	GREB1_HUMAN	Gene/Protein Processing	[13]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Norethindrone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Norethindrone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[15]
Armodafinil	DMGB035	Moderate	Increased metabolism of Norethindrone caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[16]
-----------

Coadministration of a Drug Treating the Disease Different from Norethindrone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Metreleptin	DM1NOEK	Moderate	Decreased metabolism of Norethindrone caused by Metreleptin mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[17]
Pioglitazone	DMKJ485	Minor	Increased metabolism of Norethindrone caused by Pioglitazone mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[18]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Norethindrone caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[19]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Norethindrone caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[20]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Norethindrone due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[21]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Norethindrone due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[21]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Norethindrone caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[22]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Norethindrone caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[20]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Norethindrone caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[23]
Aminophylline	DML2NIB	Moderate	Decreased metabolism of Norethindrone caused by Aminophylline.	Asthma [CA23]	[24]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Norethindrone caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[25]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Norethindrone caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[15]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Norethindrone caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[26]
Ag-221	DMS0ZBI	Moderate	Decreased metabolism of Norethindrone caused by Ag-221 mediated inhibition of CYP450 enzyme.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[17]
Pexidartinib	DMS2J0Z	Major	Increased metabolism of Norethindrone caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[27]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Norethindrone caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[28]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Norethindrone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[29]
Atorvastatin	DMF28YC	Minor	Decreased metabolism of Norethindrone caused by Atorvastatin mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[30]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Norethindrone caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[16]
Oxtriphylline	DMLHSE3	Moderate	Decreased metabolism of Norethindrone caused by Oxtriphylline.	Cough [MD12]	[24]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Norethindrone caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[31]
Ethanol	DMDRQZU	Minor	Decreased metabolism of Norethindrone caused by Ethanol.	Cystitis [GC00]	[17]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Norethindrone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[15]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Norethindrone caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[28]
Selegiline	DM6034S	Moderate	Decreased metabolism of Norethindrone caused by Selegiline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[32]
Primidone	DM0WX6I	Major	Increased metabolism of Norethindrone caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Felbamate	DM1V5ZS	Major	Increased metabolism of Norethindrone caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Oxcarbazepine	DM5PU6O	Major	Increased metabolism of Norethindrone caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Norethindrone caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[20]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Norethindrone caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[34]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Norethindrone caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Brivaracetam	DMSEPK8	Minor	Increased metabolism of Norethindrone caused by Brivaracetam mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[35]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Norethindrone caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[31]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Norethindrone caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Eslicarbazepine	DMZREFQ	Major	Increased metabolism of Norethindrone caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Norethindrone caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[19]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Norethindrone caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[23]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Norethindrone caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[23]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Norethindrone caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[23]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Norethindrone caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[20]
Boceprevir	DMBSHMF	Major	Increased metabolism of Norethindrone caused by Boceprevir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[16]
Telaprevir	DMMRV29	Major	Increased metabolism of Norethindrone caused by Telaprevir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[16]
Rifampin	DMA8J1G	Major	Increased metabolism of Norethindrone caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[36]
Rifapentine	DMCHV4I	Major	Increased metabolism of Norethindrone caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[36]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Norethindrone caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Norethindrone caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[37]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Norethindrone caused by Atazanavir mediated inhibition of UGT.	Human immunodeficiency virus disease [1C60-1C62]	[17]
BMS-201038	DMQTAGO	Moderate	Decreased metabolism of Norethindrone caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[19]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Norethindrone caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[19]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Norethindrone caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[17]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Norethindrone caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[38]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Norethindrone caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[20]
Linaclotide	DM4EGV0	Moderate	Altered absorption of Norethindrone caused by Linaclotide.	Irritable bowel syndrome [DD91]	[31]
R0-93877	DMM4U9G	Moderate	Altered absorption of Norethindrone caused by R0-93877.	Irritable bowel syndrome [DD91]	[15]
Miltefosine	DMND304	Moderate	Altered absorption of Norethindrone caused by Miltefosine.	Leishmaniasis [1F54]	[17]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Increased metabolism of Norethindrone caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[31]
Brigatinib	DM7W94S	Major	Increased metabolism of Norethindrone caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[19]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Norethindrone caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[20]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Norethindrone caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[39]
Artemether	DM48QOT	Moderate	Increased metabolism of Norethindrone caused by Artemether mediated induction of CYP450 enzyme.	Malaria [1F40-1F45]	[16]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Norethindrone caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[40]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Norethindrone caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[20]
LGX818	DMNQXV8	Major	Increased metabolism of Norethindrone caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[19]
Dabrafenib	DMX6OE3	Major	Increased metabolism of Norethindrone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[16]
Exjade	DMHPRWG	Moderate	Increased metabolism of Norethindrone caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[19]
Carfilzomib	DM48K0X	Major	Additive thrombogenic effects by the combination of Norethindrone and Carfilzomib.	Multiple myeloma [2A83]	[16]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Norethindrone caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[17]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Norethindrone caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[41]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Norethindrone caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[15]
Modafinil	DMYILBE	Moderate	Increased metabolism of Norethindrone caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[16]
E-2007	DMJDYNQ	Moderate	Increased metabolism of Norethindrone caused by E-2007 mediated induction of CYP450 enzyme.	Neuropathy [8C0Z]	[31]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Norethindrone caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[31]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Norethindrone caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[42]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Norethindrone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[43]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Norethindrone caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[28]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Norethindrone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[44]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Norethindrone caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[20]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Norethindrone due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[21]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Norethindrone due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[21]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Norethindrone and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[45]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Norethindrone due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[21]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Norethindrone due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[21]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Norethindrone due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[21]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Norethindrone due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[21]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Norethindrone due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[21]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Norethindrone caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[17]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Norethindrone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[31]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Norethindrone caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[31]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Norethindrone caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[46]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Norethindrone and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[45]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Norethindrone and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[45]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Norethindrone caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[20]
-----------


⏷ Show the Full List of 92 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Quinoline yellow WS	E00309	24671	Colorant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
--------------------


⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Norethindrone 0.35 mg tablet	0.35 mg	Oral Tablet	Oral
Norethindrone 5 mg tablet	5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Norethindrone FDA Label
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7.
7	Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chem Biol Interact. 2011 May 30;191(1-3):227-33.
8	P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.
9	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
10	The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. Int J Oncol. 2005 Jun;26(6):1507-15.
11	Novel genotoxicity assays identify norethindrone to activate p53 and phosphorylate H2AX. Carcinogenesis. 2005 Oct;26(10):1811-20. doi: 10.1093/carcin/bgi132. Epub 2005 May 19.
12	Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol Neurodegener. 2006 Jul 26;1:6. doi: 10.1186/1750-1326-1-6.
13	A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor in an MCF-7 Microarray Compendium. Chem Res Toxicol. 2021 Feb 15;34(2):313-329. doi: 10.1021/acs.chemrestox.0c00243. Epub 2021 Jan 6.
14	Picomolar norethindrone in vitro stimulates the cell proliferation and activity of a human osteosarcoma cell line and increases bone collagen synthesis without an effect on bone resorption. J Bone Miner Res. 1994 May;9(5):695-703. doi: 10.1002/jbmr.5650090515.
15	Cerner Multum, Inc. "Australian Product Information.".
16	Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.".
17	Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
18	Loi CM, Stern R, Koup JR, Vassos AB, Knowlton P, Sedman AJ "Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent." J Clin Pharmacol 39 (1999): 410-7. [PMID: 10197300]
19	Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
20	Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
21	Product Information. Cosentyx (secukinumab). Novartis Pharmaceuticals, East Hanover, NJ.
22	Product Information. Ambien (zolpidem). sanofi-aventis, Bridgewater, NJ.
23	Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33. [PMID: 2330488]
24	Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R "Effects of tobacco smoking and oral contraceptive use on theophylline disposition." Br J Clin Pharmacol 16 (1983): 271-80. [PMID: 6626419]
25	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
26	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
27	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
28	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
29	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
30	Product Information. Lipitor (atorvastatin). Parke-Davis, Morris Plains, NJ.
31	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
32	Ito D, Amano T, Sato H, Fukuuchi Y "Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease." J Neurol 248 (2001): 533-4. [PMID: 11499649]
33	Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM "Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics." Br J Clin Pharmacol 25 (1988): 527-32. [PMID: 3408633]
34	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
35	Product Information. Briviact (brivaracetam). UCB Pharma Inc, Smyrna, GA.
36	Back DJ, Breckenridge AM, Crawford F, et al. "The effect of rifampicin on norethisterone pharmacokinetics." Eur J Clin Pharmacol 15 (1979): 193-7. [PMID: 37091]
37	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
38	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
39	Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
40	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
41	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
42	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
43	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
44	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
45	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
46	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.